## The expression of CXCR4, CXCL12 and CXCR7 in malign

Journal of Pathology 223, 519-530 DOI: 10.1002/path.2829

Citation Report

#	Article	IF	CITATIONS
1	The expression of Dishevelled-3 and glutamine metabolism in malignant pleural mesothelioma. Journal of Clinical Pathology, 2012, 65, 855-858.	1.0	5
2	Current status of chemokine receptor inhibitors in development. Immunology Letters, 2012, 145, 68-78.	1.1	55
3	Imaging agents for the chemokine receptor 4 (CXCR4). Chemical Society Reviews, 2012, 41, 5239.	18.7	76
4	Inhibition of <scp>CK</scp> 2α downâ€regulates Notch1 signalling in lung cancer cells. Journal of Cellular and Molecular Medicine, 2013, 17, 854-862.	1.6	48
5	CXCR7 Is Highly Expressed in Acute Lymphoblastic Leukemia and Potentiates CXCR4 Response to CXCL12. PLoS ONE, 2014, 9, e85926.	1.1	49
6	Altered Protease–Activated Receptor-1 Expression and Signaling in a Malignant Pleural Mesothelioma Cell Line, NCI-H28, with Homozygous Deletion of the β-Catenin Gene. PLoS ONE, 2014, 9, e111550.	1.1	10
7	CK2α, over-expressed in human malignant pleural mesothelioma, regulates the Hedgehog signaling pathway in mesothelioma cells. Journal of Experimental and Clinical Cancer Research, 2014, 33, 93.	3.5	20
8	SDFâ€1α induces differential trafficking of CXCR4 XCR7 involving cyclophilin A, CXCR7 ubiquitination and promotes platelet survival. FASEB Journal, 2014, 28, 2864-2878.	0.2	55
9	Differential Expression of SDF-1 Isoforms in Bladder Cancer. Journal of Urology, 2014, 191, 1899-1905.	0.2	15
10	Radiation-induced pulmonary injury accelerated pulmonary metastasis in a mouse model of breast cancer. Oncology Letters, 2015, 10, 3613-3618.	0.8	14
11	Positron Emission Tomographic Imaging of CXCR4 in Cancer: Challenges and Promises. Molecular Imaging, 2015, 14, 7290.2014.00041.	0.7	16
12	MicroRNAs as potential biomarkers in malignant pleural mesothelioma. Current Biomarker Findings, 0, , 1.	0.4	0
13	Critical roles of chemokine receptor CCR5 in regulating glioblastoma proliferation and invasion. Acta Biochimica Et Biophysica Sinica, 2015, 47, 890-898.	0.9	36
14	CXCR4 and CCR7: Two eligible targets in targeted cancer therapy. Cell Biology International, 2016, 40, 955-967.	1.4	47
15	Inhibition of CXCR4 and CXCR7 for reduction of cell proliferation and invasion in human endometrial cancer. Tumor Biology, 2016, 37, 7473-7480.	0.8	16
16	Targeting YAP in malignant pleural mesothelioma. Journal of Cellular and Molecular Medicine, 2017, 21, 2663-2676.	1.6	55
17	DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma. International Journal of Oncology, 2017, 51, 91-103.	1.4	7
18	The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy. Frontiers in Oncology, 2019, 9, 1366.	1.3	50

CITATION REPORT

#	Article	IF	CITATIONS
19	Experimental study of the inhibition effect of CXCL12/CXCR4 in malignant pleural mesothelioma. Journal of Investigative Medicine, 2019, 67, 338-345.	0.7	2
20	The Chemokine Receptor CXCR4 in Cell Proliferation and Tissue Regeneration. Frontiers in Immunology, 2020, 11, 2109.	2.2	142
21	CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent. Pharmacological Research, 2020, 159, 105010.	3.1	61
22	Exploring the â€~Dormancy Activation Switch' in the Tumour Microenvironment for Metastatic Lung Cancer: The Possible Role of MicroRNA. , 2021, , 191-215.		0
23	CXCR4 engagement triggers CD47 internalization and antitumor immunization in a mouse model of mesothelioma. EMBO Molecular Medicine, 2021, 13, e12344.	3.3	11
24	The Immune System of Mesothelioma Patients: A Window of Opportunity for Novel Immunotherapies. , 0, , .		0
25	Targeting CXCR4 with [68Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?. Oncotarget, 2017, 8, 96732-96737.	0.8	17
26	Low-dose photon irradiation induces invasiveness through the SDF-1α/CXCR4 pathway in malignant mesothelioma cells. Oncotarget, 2017, 8, 68001-68011.	0.8	4
27	Upregulation of chemokine receptor CCR10 is essential for glioma proliferation, invasion and patient survival. Oncotarget, 2014, 5, 6576-6583.	0.8	22
28	Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells. Oncotarget, 2015, 6, 4357-4368.	0.8	88
29	Reactive oxygen species a double-edged sword for mesothelioma. Oncotarget, 2015, 6, 16848-16865.	0.8	70
30	Mesenchymal stem cell recruitment by stromal derived factor-1-delivery systems based on chitosan/poly(γ-glutamic acid) polyelectrolyte complexes. , 2012, 23, 249-261.		46
31	Mesothelioma and Hypoxia: Modulation of the Inflammation-Related Phenotype and Identification of Prognostic Markers. Journal of Cancer Science & Therapy, 2014, 06, .	1.7	0
32	CK2¿, over-expressed in human malignant pleural mesothelioma, regulates the Hedgehog signaling pathway in mesothelioma cells. Journal of Experimental and Clinical Cancer Research, 2014, 33, 93.	3.5	7
33	Immune Biomarkers in Paediatric Malignancies. , 2018, , 259-273.		0
35	CXCR4-targeted theranostics in oncology. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4133-4144.	3.3	48
36	Current Status of 68Ga-Pentixafor in Solid Tumours. Diagnostics, 2022, 12, 2135.	1.3	3